Scarica l'app Stockscreener
15.25
1.49%
-0.23
Dopo l'orario di chiusura:
15.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$15.48
Aprire:
$15.5
Volume 24 ore:
2.64M
Relative Volume:
0.50
Capitalizzazione di mercato:
$11.84B
Reddito:
$220.00K
Utile/perdita netta:
$-1.21B
Rapporto P/E:
-9.5081
EPS:
-1.6039
Flusso di cassa netto:
$-387.48M
1 W Prestazione:
-1.10%
1M Prestazione:
+16.86%
6M Prestazione:
-22.51%
1 anno Prestazione:
-41.07%
Intervallo 1D:
$14.86
$15.53
Intervallo di 1 settimana:
$14.86
$16.05
Portata 52W:
$12.55
$30.98
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.25 | 11.84B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics (SMMT) Q1 2025 earnings summary - Quartr
Why is SMMT stock tumbling today? - MSN
Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary - Quartr
Price to sales forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update - Stocktwits
Price to book forward of Summit Therapeutics Inc. – NASDAQ:SMMT - TradingView
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 85% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
If You Invested $1,000 in Summit Therapeutics Inc (SMMT) - Stock Titan
Understanding Momentum Shifts in (SMMT) - Stock Traders Daily
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering? - Sahm
Summit Therapeutics Inc Actuals & Estimates (NASDAQ:SMMT) - TradingView
Summit Therapeutics Inc Actuals & Estimates (BMV:SMMT) - TradingView
SMMT Forecast — Price Target — Prediction for 2027 - TradingView
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics finance chief tops list of public CFO pay in 2025 - CFO.com
Bernstein raises Summit Therapeutics stock price target on trial outlook By Investing.com - Investing.com Australia
Bernstein raises Summit Therapeutics stock price target on trial outlook - Investing.com
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing - Insider Monkey
Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT) - Seeking Alpha
Bernstein Maintains Summit Therapeutics(SMMT.US) With Sell Rating, Raises Target Price to $9.8 - Moomoo
Summit Therapeutics (SMMT) Q4 2025 earnings summary - Quartr
5 Most Promising Healthcare Stocks According to Wall Street Analysts - Insider Monkey
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Avoiding Lag: Real-Time Signals in (SMMT) Movement - Stock Traders Daily
Summit rebounds after nearly $50M insider purchase - MSN
Summit Therapeutics Inc (SMMT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Institutional Confidence - TradingKey
Summit Therapeutics Inc (SMMT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Summit Therapeutics Inc (SMMT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Summit Therapeutics Inc (SMMT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Summit Therapeutics Inc (SMMT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Summit Therapeutics Inc (SMMT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why Summit Therapeutics Is Staying In The Biotechnology Spotlight? - Kalkine Media
Should Summit Therapeutics’ Canceled US$500 Million Equity Offering Reshape SMMT Investors’ View on Financing Strategy? - Sahm
Summit Therapeutics: Getting A Foot In The Door Isn't Getting Through It (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Inc. (SMMT) Investor Outlook: Evaluating A Potential 103.85% Upside - DirectorsTalk Interviews
Summit Therapeutics Raises $500 Million in Public Offering to Support Lung Cancer PipelineGAAP Earnings Report - newsline.com
SMMT Jumps As Summit Therapeutics Rides Ivonescimab Momentum - timothysykes.com
Summit Therapeutics stockholders approve directors and incentive plan - The Globe and Mail
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering - Insider Monkey
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):